Cell Therapy News/Articles, page-11683

First 11683 Last

Share
Profile

Follow
Wilba32

6,947 Posts.

1527

25/09/21

20:50

Post #: 56349862
Share

Originally posted by Mani86: ↑

Copied
Interesting Case Study . Can something like this happen for Mesoblast? see below

In stunning reversal, FDA clears Sarepta DMD drug it rejected 4 months ago
by Angus Liu

The FDA’s attitude toward Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) therapies is nothing short of dramatic. In just four months, the agency shocked industry watchers twice, first with a rejection and now a reversal for the biotech’s Exondys 51 follow-on.

Out of nowhere, the agency Thursday granted accelerated approval to Sarepta’s Vyondys 53 (golodirsen), a drug it turned down in August for safety reasons. The go-ahead covers about 8% Duchenne patients whose dystrophin gene bears a certain mutation amenable to exon 53 skipping.

While the FDA didn’t elaborate on the sudden change of course, Sarepta said it had launched a formal dispute resolution request after receiving the agency's complete response letter (CRL) detailing its reasons for the rejection. Sarepta worked with Peter Stein, director of the FDA's Office of New Drugs, to resolve the concerns raised in that CRL.

In August, a stunned Sarepta said the FDA had rejected Vyondys 53 for the risk of infection linked to intravenous infusion ports and for kidney toxicity seen only in animal studies. Analysts suspected at the time that the agency had changed its standards on using dystrophin as a surrogate marker for approval. DMD patients lack dystrophin, a protein that helps maintain the structure of skeletal muscle fibers, due to missing exons in the DMD gene.

Controversy erupted in 2016 when Sarepta’s Exondys 51 won an FDA thumbs-up based on dystrophin data without showing actual clinical benefits such as improvement on disease progression. Opinions were split even within the FDA; in fact, two officials who'd opposed the green light decided to retire. In contrast, European regulators shot down Exondys 51 last September—for the second time.

Like Exondys 51, Vyondys 53 was approved based only on dystrophin production “that is reasonably likely to predict clinical benefit” in DMD patients, the FDA said in a statement—not on proven clinical improvements. In a small clinical trial, 25 patients on Vyondys 53 saw 1.02% of normal dystrophin production after 48 weeks of treatment, up from 0.1% at baseline.

Expand

I now believe anything could happen … now if it were to happen fast …

MSB Price at posting: $1.72 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

There are more pages in this discussion • 6,579 more messages in this thread...

First 11683 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.51		Change 0.020(1.34%)		Mkt cap ! $1.689B

Open	High	Low	Value	Volume
$1.57	$1.58	$1.41	$11.92M	7.979M

Buyers (Bids)

No.	Vol.	Price($)
12	30148	$1.51

Sellers (Offers)

Price($)	Vol.	No.
$1.51	70629	12

View Market Depth

No.	Vol.	Price($)
14	32476	1.505
12	42639	1.500
6	20357	1.495
9	83315	1.490
10	113181	1.485

Price($)	Vol.	No.
1.510	60629	11
1.515	125790	7
1.520	249924	13
1.525	27376	6
1.530	146820	6

Last trade - 12.57pm 07/10/2024 (20 minute delay)

MSB (ASX) Chart

Cell Therapy News/Articles, page-11683

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Cell Therapy News/Articles, page-11683

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News